Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension.

Byrd JB, Brook RD.

J Hum Hypertens. 2014 Jan;28(1):3-9. doi: 10.1038/jhh.2013.42. Epub 2013 May 23. Review.

PMID:
23698003
2.

Reviving the use of aldosterone inhibitors in treating hypertension in obesity.

Huby AC, Belin De Chantemèle EJ.

Am J Physiol Regul Integr Comp Physiol. 2015 Nov 1;309(9):R1065-7. doi: 10.1152/ajpregu.00133.2015. Epub 2015 Jul 8. Review.

PMID:
26157057
3.

Aldosterone and mineralocorticoid receptors in the cardiovascular system.

Funder JW.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):393-400. doi: 10.1016/j.pcad.2009.12.003. Review.

PMID:
20226957
4.

Mineralocorticoid-induced sodium appetite and renal salt retention: evidence for common signaling and effector mechanisms.

Fu Y, Vallon V.

Nephron Physiol. 2014;128(1-2):8-16. doi: 10.1159/000368264. Epub 2014 Nov 6. Review.

5.

Aldosterone and refractory hypertension.

Nyirenda MJ, Padfield PL.

Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):213-8. Review.

PMID:
17940442
6.

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Whaley-Connell A, Johnson MS, Sowers JR.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004. Review.

7.

Role of mineralocorticoid action in the brain in salt-sensitive hypertension.

Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE.

Clin Exp Pharmacol Physiol. 2012 Jan;39(1):90-5. doi: 10.1111/j.1440-1681.2011.05538.x. Review.

8.

Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Bomback AS, Klemmer PJ.

Am J Nephrol. 2009;30(2):140-6. doi: 10.1159/000209744. Epub 2009 Mar 20. Review.

9.

Mineralocorticoid receptor activation in obesity hypertension.

Nagase M, Fujita T.

Hypertens Res. 2009 Aug;32(8):649-57. doi: 10.1038/hr.2009.86. Epub 2009 Jun 12. Review.

PMID:
19521418
10.

Drug mechanisms to help in managing resistant hypertension in obesity.

Jansen PM, Danser JA, Spiering W, van den Meiracker AH.

Curr Hypertens Rep. 2010 Aug;12(4):220-5. doi: 10.1007/s11906-010-0123-5. Review.

11.

Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells.

Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR.

Endocr Res. 2004 Nov;30(4):865-70.

PMID:
15666838
12.

Mineralocorticoid receptor antagonists and the metabolic syndrome.

Tirosh A, Garg R, Adler GK.

Curr Hypertens Rep. 2010 Aug;12(4):252-7. doi: 10.1007/s11906-010-0126-2. Review.

13.

The association of aldosterone with obesity-related hypertension and the metabolic syndrome.

Vogt B, Bochud M, Burnier M.

Semin Nephrol. 2007 Sep;27(5):529-37. Review.

PMID:
17868790
14.

Obesity, sleep apnea, aldosterone, and hypertension.

Goodfriend TL.

Curr Hypertens Rep. 2008 Jun;10(3):222-6. Review.

PMID:
18765094
15.

Are there unknown mineralocorticoids in low-renin essential hypertension?

Hollifield JW, Slaton PE, Wilson HM, Sennett JA, Yarbro L, Island DP, Liddle GW.

Mayo Clin Proc. 1977 May;52(5):329-33.

PMID:
323587
16.

Aldosterone, mineralocorticoid receptors and vascular inflammation.

Funder JW.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):263-9. Review.

PMID:
15134827
17.

Increased aldosterone: mechanism of hypertension in obesity.

Flynn C.

Semin Nephrol. 2014 May;34(3):340-8. doi: 10.1016/j.semnephrol.2014.04.009. Epub 2014 Apr 16. Review.

PMID:
25016404
18.

Aldosterone receptor antagonists for hypertension: what do they offer?

Liew D, Krum H.

Drugs. 2003;63(19):1963-72. Review.

PMID:
12962513
20.

Aldosterone receptor antagonists: current perspectives and therapies.

Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI.

Vasc Health Risk Manag. 2013;9:321-31. doi: 10.2147/VHRM.S33759. Epub 2013 Jun 24. Review.

Items per page

Supplemental Content

Write to the Help Desk